High dose therapy and autologous or allogeneic hematopoietic cell transplantation has proven to be effective therapy for patients with multiple myeloma. However, with both forms of therapy, there is a continuous relapse risk. We propose to treat patients with multiple myeloma using a non-myeloablative mixed chimeric allogeneic transplant along with donor-derived dendritic cells ands idiotype vaccinations. Based upon our prior work we will be using the immunoglobulin idiotype produced by each patient's tumor as the specific antigen along with dendritic cells obtained from the patient's hematopoietic cell donor. Each patient will have the immunoglobulin produced by his/her myeloma cells isolated and purified for use as a vaccine. The patients are treated with sequential autologous and non- myeloablative allogeneic hematopoietic cell transplants. The autologous transplant is used as a cytoreductive step prior to the non- myeloablative allogeneic transplant. The immunosuppressive drugs used to prevent graft-vs-host disease are decreased so that most patients are expected to be off all immunosuppression six months following the allogeneic transplant maneuver. Approximately nine months following the allogeneic transplant procedure, dendritic cells will be obtained by leukapheresis from the donor. These cells will be pulsed with the idiotype protein and then infused into the patient on two occasions, followed by a series of monthly injections of idiotype protein coupled to a carrier protein and mixed with an immunologic adjuvant. The patients will be evaluated for their immune responses against the idiotype protein and signs of graft-versus-host disease. Novel assays will be performed for the detection of cytotoxic T-cells directed against the tumor idiotype. Quantitative PCR will be performed to assess tumor burden. The basic question posed in this project is whether an effective anti- tumor immune response can be induced in patients with multiple myeloma which can augment the therapeutic effect of an allogeneic hematopoietic cell transplant. In this study we will be observing the clinical outcome of the transplant maneuver, as well as molecular correlates of disease, although the proposed initial study is not designed to prove clinical efficacy of the vaccination series. The primary endpoints will be the documentation of immune responses which we hope will be enhanced by allogeneic dendritic cells. If the initial trial shows promising results, appropriate prospective studies will be designed to demonstrate the efficacy of this novel approach.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA049605-14
Application #
6609106
Study Section
Project Start
2002-07-11
Project End
2007-02-28
Budget Start
Budget End
Support Year
14
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Muffly, Lori; Sheehan, Kevin; Armstrong, Randall et al. (2018) Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv 2:681-690
Tavallaee, Mahkam; Steiner, David F; Zehnder, James L et al. (2018) Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol :
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Nybakken, Grant E; Bala, Rajeev; Gratzinger, Dita et al. (2016) Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications. PLoS One 11:e0151735
Zhang, Bing; Zehnder, James L (2016) ROS: novel regulators of thrombopoiesis. Blood 128:613-4

Showing the most recent 10 out of 307 publications